Hepatitis C (genotype 1) - boceprevir (TA253)
NICE recommends boceprevir with peginterferon alfa and ribavirin as a possible treatment for genotype 1 chronic hepatitis C in adults with the earlier stages of liver disease (known as compensated liver disease).
Who can have boceprevir?
You should be able to have boceprevir with peginterferon alfa and ribavirin if:
- you have not been treated for genotype 1 chronic hepatitis C before or
- you have been treated for genotype 1 chronic hepatitis C before but your treatment did not work.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended boceprevir because it works better than other treatments available on the NHS. Although it also costs more than other treatments, this was justified by the benefits it provided.
This page was last updated: 07 September 2012
- Web format
- Full Guidance (PDF)
- TA253 Boceprevir ar gyfer hepatitis C cronig genoteip 1: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.